Download RCPsych Literature Search COMORBIDITY 2007

COMORBIDITY<4>
Database EMBASE
Accession Number 2007252029
Authors DeMarce J.M. Burden J.L. Lash S.J. Stephens R.S. Grambow S.C.
Institutio
(DeMarce, Burden, Lash) Veterans Affairs Medical Center, 1970 Roanoke Blvd, Salem, VA 24153, United States.
(DeMarce, Stephens) Virginia Polytechnic Institute, State University, Virginia Tech, Blacksburg, VA 24061, United
States.
(Burden, Lash) University of Virginia, Salem, VA 24153, United States.
(Grambow) Center for Health Services Research in Primary Care, Durham VA Medical Center, Durham, NC 27710,
United States.
(Grambow) Duke University Medical Center, (DUMC) Hock Plaza Room: 11031, Durham, NC 27710, United
States.
Country of Publication
United Kingdom
Title
Convergent validity of the Timeline Followback for persons with comorbid psychiatric
disorders engaged in residential substance use treatment.
Source
Addictive Behaviors. 32(8)(pp 1582-1592), 2007. Date of Publication: Aug 2007.
Abstract
This study examined the convergent validity of the Timeline Followback (TLFB) for
individuals with comorbid (Axis I and/or Axis II) psychiatric disorders in a sample of persons
(N = 150) engaged in residential treatment for substance use disorders (SUDs).
Approximately one-half of the sample was diagnosed with at least one comorbid psychiatric
disorder. Validity was assessed comparing data from the TLFB with data from the Addiction
Severity Index (ASI) and collateral reports. For the entire sample, data from the TLFB was
significantly correlated with data from the ASI and collateral reports of substance use. No
significant differences were found between those with and those without a comorbid
psychiatric disorder, suggesting that the TLFB was equally valid for both groups. copyright
2006.
ISSN 0306-4603
Publication Type Journal: Article
Journal Name Addictive Behaviors
Volume 32
Issue Part 8
Page 1582-1592
Year of Publication 2007
Date of Publication Aug 2007
COMORBIDITY <8>
Database EMBASE
Accession Number 2007246757
Authors Ouimette P. Coolhart D. Funderburk J.S. Wade M. Brown P.J.
Institution
(Ouimette) Center for Integrated Healthcare, Syracuse VA Medical Center, SUNY Upstate Medical University,
Syracuse, NY, United States.
(Coolhart, Funderburk, Wade) Center for Integrated Healthcare, Syracuse VA Medical Center, Syracuse, NY, United
States.
Country of Publication
United Kingdom
Title
Precipitants of first substance use in recently abstinent substance use disorder
patients with PTSD.
Source
Addictive Behaviors. 32(8)(pp 1719-1727), 2007. Date of Publication: Aug 2007.
Abstract
Patients with substance use (SUD) and posttraumatic stress disorders (PTSD) are at high
risk for relapse. This study examined the reasons patients identify for their first substance use
following discharge from SUD treatment. A total of 65 patients with and without PTSD
completed clinical interviews, including an adapted version of the Relapse Interview [RI;
Miller, W.R., & Marlatt, G.A. (1996). Appendix A: Relapse Interview. Addiction, 91(Suppl),
231-240.] at a 6-month follow-up. Qualitative data from the RI was consensus coded using
Marlatt's taxonomy of relapse situations. Results indicated that patients with PTSD were less
likely to report first substance use triggered by cue-based urges and more likely to report use
in response to negative emotions of an interpersonal nature than those patients without
PTSD. Other characteristics of first use associated with PTSD included greater subjective
urges right before using, greater efforts to obtain substances and more likelihood to use to
intoxication. Patients with unremitted PTSD reported poorer outcome and self-efficacy
expectations than those without PTSD or with remitted PTSD. Implications for self-medication
theory and clinical practice are discussed. copyright 2006 Elsevier Ltd. All rights reserved.
ISSN 0306-4603
Publication Type Journal: Article
Journal Name Addictive Behaviors
Volume 32
Issue Part 8
Page 1719-1727
Year of Publication 2007
Date of Publication Aug 2007
COMORBIDITY <20>
Database EMBASE
Accession Number 2007386334
Authors Rounsaville B.J.
Institution
(Rounsaville) VA CT Healthcare System, 950 Campbell Avenue (151D), West Haven, CT 06516, United States.
Country of Publication
United Kingdom
Title
DSM-V research agenda: Substance abuse/psychosis comorbidity.
Source
Schizophrenia Bulletin. 33(4)(pp 947-952), 2007. Date of Publication: Jun 2007.
Abstract
For diagnosis of patients with comorbid psychotic symptoms and substance use disorders
(SUDs), Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, makes clear
distinctions between independent psychotic disorders (eg, bipolar disorder, schizophrenia)
and substance-induced syndromes (eg, delirium, dementias). Most substance-induced
psychotic symptoms are considered to be short lived and to resolve with sustained abstinence
along with other symptoms of substance intoxication and withdrawal. These guidelines are
challenged by practical difficulties in distinguishing between substance-induced and
independent psychoses and by mounting evidence that marijuana use may be a contributing
cause of schizophrenia. To inform the diagnostic distinction between substance-induced vs
independent psychotic symptoms, 2 kinds of information could be sought from longitudinal
research: (a) identification of early markers that clearly differentiate the 2 conditions and (b)
more precise information about duration of psychotic symptoms induced by different
substances. Evidence of this type could emerge from reanalysis of existing data from largescale longitudinal studies of community samples. To inform possible nosological changes
related to the possible schizophrenia-inducing role of marijuana (eg, designating a "cannabisinduced" subtype), a wide range of research evidence will be needed to clarify the
relationship between effects of cannabis and schizophrenia symptoms. Ultimately, the ideal
psychiatric nomenclature will define syndromes on the basis of established etiology and/or
pathophysiology. Given the strong association between SUDs and psychotic disorders,
research on the neurobiology of psychotic disorders could fruitfully include subjects with
comorbid SUDs to shed light on shared etiology and pathophysiology. copyright The Author
2007. Published by Oxford University Press on behalf of the Maryland Psychiatric Research
Center. All rights reserved.
ISSN 0586-7614
Publication Type Journal: Conference Paper
Journal Name Schizophrenia Bulletin
Volume 33
Issue Part 4
Page 947-952
Year of Publication 2007
Date of Publication Jun 2007
COMORBIDITY <36>
Database EMBASE
Accession Number 2007385291
Authors Trathen B. O'Gara C. Sarkhel A. Sessay M. Rao H. Luty J.
Institution
(Trathen) CDAT, 2nd floor Aylmer House, Kitson Way, Harlow, Essex CM20 1DL, United Kingdom.
(O'Gara) Maudsley Hospital, Institute of Psychiatry, United Kingdom.
(Sarkhel, Rao, Luty) The Taylor Centre, Essex Street, Southend on Sea, Essex SS4 1RB, United Kingdom.
(Sessay) Merton Community Drug Team, Springfield Hospital, 61 Glenburnie Road, London, SW17 7DJ, United
Kingdom.
Country of Publication
United Kingdom
Title
Co-morbidity and cannabis use in a mental health trust in South East England.
Source
Addictive Behaviors. 32(10)(pp 2164-2177), 2007. Date of Publication: Oct 2007.
Abstract
Aim: The prevalence of co-morbidity (severe mental illness and substance) may be less in
rural and semi-rural areas than inner cities. The aims were therefore to measure the
prevalence of co-morbidity among patients of attending a mental health service in a semi-rural
area South East England. Design and participants: Cross-sectional prevalence survey of
1808 patients with detailed assessments from a representative sample of 373 patients
identified as having a combination of severe mental illness and substance misuse. Interviews
with key workers were performed using validated methods from the COSMIC study. Results:
The response rates equalled or exceeded 90% for the various parts of the study. One-tenth of
patients attending the Community Mental Health Teams (CMHTs) reported problematic use of
illicit drugs and 17% reported alcohol problems in the past year. 22% of Community Drug and
Alcohol Service (CDAS) clients reported a severe mental illness and 46% reported some
other form of psychiatric disorder. Of patients with a combined diagnosis of mental illness and
substance misuse, cannabis use was 4-fold more common amongst patients attending the
CMHT than CDAS (33% vs. 8%) while use of amphetamine was five-fold higher in the CMHT
group (10% vs. 2%). Patients with concurrent psychiatric and substance misuse problems
represent a similar proportion of the aggregate caseload of both treatment services with
observed prevalence amongst the CDAS and CMHT patients with a diagnosis for anxiety
disorder (18% vs. 26%), minor depression (42% vs. 32%), personality disorders (32% vs.
36%), histories of self-harm (52% vs. 46%) and violence (33% vs. 30%) respectively.
Conclusions: Co-morbidity is common in clients amongst CMHT and CDAS clients although
use of cannabis was significantly more common in CMHT clients than in CDAS clients.
copyright 2007 Elsevier Ltd. All rights reserved.
ISSN 0306-4603
Publication Type Journal: Article
Journal Name Addictive Behaviors
Volume 32
Issue Part 10
Page 2164-2177
Year of Publication 2007
Date of Publication Oct 2007
COMORBIDITY <42>
Database EMBASE
Accession Number 2007380542
Authors Resnick H.S. Acierno R. Amstadter A.B. Self-Brown S. Kilpatrick D.G.
Institution
(Resnick, Acierno, Amstadter, Self-Brown, Kilpatrick) Department of Psychiatry and Behavioral Sciences, Medical
University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425-0742, United States.
Country of Publication
United Kingdom
Title
An acute post-sexual assault intervention to prevent drug abuse: Updated findings.
Source
Addictive Behaviors. 32(10)(pp 2032-2045), 2007. Date of Publication: Oct 2007.
Abstract
Sexual assault and rape routinely produce extreme distress and negative psychological
reactions in victims. Further, past research suggests that victims are at increased risk of
developing substance use or abuse post-rape. The post-rape forensic medical exam may
itself exacerbate peritraumatic distress because it includes cues that may serve as reminders
of the assault, thereby potentiating post-assault negative sequelae. To address these
problems, a two-part video intervention was developed to take advantage of the existing
sexual assault forensic exam infrastructure, and to specifically (a) minimize anxiety/discomfort
during forensic examinations, thereby reducing risk of future emotional problems, and (b)
prevent increased substance use and abuse following sexual assault. Updated findings with a
sample of 268 sexual assault victims participating in the forensic medical exam and
completing one or more follow-up assessments at: (1)< 3 months post-assault; (2) 3 to 6
months post-assault; or (3) 6 months or longer post-assault indicated that the video was
associated with significantly lower frequency of marijuana use at each time point, among
women who reported use prior to the assault. copyright 2007 Elsevier Ltd. All rights reserved.
ISSN 0306-4603
Publication Type Journal: Article
Journal Name Addictive Behaviors
Volume 32
Issue Part 10
Page 2032-2045
Year of Publication 2007
Date of Publication Oct 2007
COMORBIDITY <51>
Database EMBASE
Accession Number 2007373369
Authors Borras L. Huguelet P.
Institution
(Borras, Huguelet) Department of Psychiatry, University Hospital of Geneva, Division of Adult Psychiatry, Geneva,
Switzerland.
(Borras) University Hospital of Geneva, Department of Psychiatry, Division of Adult Psychiatry, 36 Rue du XXXI
Decembre, Geneva, 1207, Switzerland.
Country of Publication
United Kingdom
Title
Schizophrenia and pathological gambling.
Source
American Journal on Addictions. 16(4)(pp 269-271), 2007. Date of Publication: Jul 2007.
Abstract
High rates of pathological gambling are found in psychiatric populations, including those with
mood or substance use disorders. The extent to which individuals with schizophrenia exhibit
the symptoms of pathological gambling has not been adequately investigated. This paper
examines the case of a 40-year-old schizophrenic female with a four-year history of gambling.
The characteristics of possible interactions between pathological gambling and schizophrenic
symptom profiles are outlined in order to propose better treatments for this group of patients.
Copyright copyright American Academy of Addiction Psychiatry.
ISSN 1055-0496
Publication Type Journal: Article
Journal Name American Journal on Addictions
Volume 16
Issue Part 4
Page 269-271
Year of Publication 2007
Date of Publication Jul 2007
COMORBIDITY <52>
Database EMBASE
Accession Number 2007373368
Authors Akerele E. Levin F.R.
Institution
(Akerele) Department of Psychiatry, Harlem Hospital, Columbia University, New York, NY, United States.
(Levin) Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, United
States.
(Akerele) Department of Psychiatry, 506 Lenox Avenue, New York, NY 10037, United States.
Country of Publication
United Kingdom
Title
Comparison of olanzapine to risperidone in substance-abusing individuals with
schizophrenia.
Source
American Journal on Addictions. 16(4)(pp 260-268), 2007. Date of Publication: Jul 2007.
Abstract
A 14-week double blind study compared the efficacy of olanzapine to risperidone in reducing
marijuana/cocaine craving and use in individuals with schizophrenia. The study consisted of
three phases: a two-week assessment phase, a two-week cross-taper phase onto
olanzapine/risperidone, and a ten-week period of maintenance on olanzapine/risperidone.
The proportion of cocaine-positive urines decreases over time for both groups with a trend for
a greater reduction for the olanzapine group compared to risperidone group. In the last six
weeks, marijuana craving was more likely for the risperidone group compared to the
olanzapine group, although there was no group difference in the proportion of negative
marijuana urines. The data suggest some potential for the utility of olanzapine for the
treatment of cocaine dependence in individuals with schizophrenia. Copyright copyright
American Academy of Addiction Psychiatry.
ISSN 1055-0496
Publication Type Journal: Article
Journal Name American Journal on Addictions
Volume 16
Issue Part 4
Page 260-268
Year of Publication 2007
Date of Publication Jul 2007
COMORBIDITY <53>
Database EMBASE
Accession Number 2007373367
Authors Rubin E. Aharonovich E. Bisaga A. Levin F.R. Raby W.N. Nunes E.V.
Institution
(Rubin, Aharonovich, Bisaga, Levin, Raby, Nunes) Department of Psychiatry, College of Physicians and Surgeons,
Columbia University, New York, NY, United States.
(Rubin) New York State Psychiatric Institute, 1051 Riverside Dr., New York, NY 10032, United States.
Country of Publication
United Kingdom
Title
Early abstinence in cocaine dependence: Influence of comorbid major depression.
Source
American Journal on Addictions. 16(4)(pp 283-290), 2007. Date of Publication: Jul 2007.
Abstract
Cocaine dependence (CD) is often accompanied by major depressive disorder (MDD). The
comorbid condition (CD + MDD) is especially difficult to treat, with relapse possibly made
more likely by intensified dysphoria during abstinence in the setting of MDD. We studied
treatment-seeking CD + MDD volunteers, currently depressed, and a comparison CD group
over three days of inpatient monitored abstinence. At admission, Beck Depression Inventory
(BDI) and anxiety scores differed significantly between groups. By Day 3, BDI scores
improved for both CD and CD + MDD groups. The mood response to cocaine cessation
among CD + MDD individuals resembled that of CD participants, contrary to some
expectations. Copyright copyright American Academy of Addiction Psychiatry.
ISSN 1055-0496
Publication Type Journal: Article
Journal Name American Journal on Addictions
Volume 16
Issue Part 4
Page 283-290
Year of Publication 2007
Date of Publication Jul 2007
COMORBIDITY <54>
Database EMBASE
Accession Number 2007373366
Authors Batki S.L. Dimmock J.A. Wade M. Gately P.W. Cornell M. Maisto S.A. Carey K.B. Ploutz-Snyder R.
Institution
(Batki, Dimmock, Gately, Cornell, Maisto, Carey, Ploutz-Snyder) Department of Psychiatry, SUNY Upstate Medical
University, Syracuse, NY, United States.
(Batki, Wade, Maisto) VA Center for Integrated Healthcare, Syracuse, NY, United States.
(Batki) Hutchings Psychiatric Center, New York State Office of Mental Health, Syracuse, NY, United States.
(Maisto, Carey) Department of Psychology, Syracuse University, Syracuse, NY, United States.
(Batki) Addiction Psychiatry Research Program, Department of Psychiatry, SUNY Upstate
Medical University, 750 East Adams Street, Syracuse, NY 13210, United States.
Country of Publication
United Kingdom
Title
Monitored naltrexone without counseling for alcohol abuse/dependence in
schizophrenia-spectrum disorders.
Source
American Journal on Addictions. 16(4)(pp 253-259), 2007. Date of Publication: Jul 2007.
Abstract
This clinical trial assessed the effects of monitored naltrexone treatment in 19 subjects with
schizophrenia spectrum and alcohol use disorders in an eight-week prospective open pilot
study. Naltrexone was directly administered to subjects in oral doses of 100 mg on Mondays
and Wednesdays, and 150 mg on Fridays. Subjects received reimbursement for attending the
three weekly study visits. Subjects continued to receive their usual psychiatric care with no
added alcohol counseling provided. Alcohol use was assessed by self-report and biomarkers.
Psychosis severity was measured by the Positive and Negative Syndrome Scale (PANSS).
Subjects reported significant reductions in their number of drinks per week, drinks per drinking
day, days of drinking to intoxication, and alcohol craving. Subjects also showed significant
reductions in Addiction Severity Index (ASI) alcohol composite scores and in PANSS positive,
negative and general psychopathology scores. Copyright copyright American Academy of
Addiction Psychiatry.
ISSN 1055-0496
Publication Type Journal: Article
Journal Name American Journal on Addictions
Volume 16
Issue Part 4
Page 253-259
Year of Publication 2007
Date of Publication Jul 2007
COMORBIDITY <96>
Database EMBASE
Accession Number 2007325476
Authors Henwood B. Padgett D.K.
Institution
(Henwood, Padgett) New York University, School of Social Work, New York, NY, United States.
(Henwood) c/o NYSS, 838 Broadway, New York, NY 10003, United States.
Country of Publication
United Kingdom
Title
Reevaluating the self-medication hypothesis among the dually diagnosed.
Source
American Journal on Addictions. 16(3)(pp 160-165), 2007. Date of Publication: May 2007.
Abstract
The self-medication hypothesis (SMH) is an intuitively appealing explanation for substance
use. Conceptually, however, it is not always clear what the hypothesis entails, particularly
when applied to persons with mental and substance use disorders. This makes empirical
support for SMH difficult to evaluate. By classifying the self-reported reasons for substance
use from 33 participants in a NIMH-funded qualitative study of dual diagnosis and
homelessness, this study aims to evaluate the applicability of SMH. How one conceptualizes
SMH will determine whether SMH is empirically supported. When SMH refers to using
substances strictly to cope with symptoms of mental disorders, only 11 out of 72 attributions
support it. When SMH refers to using substances to cope with painful feelings in general,
more than half of all attributions support SMH. The significance of accurately understanding
the various reasons people give for why they use substances is discussed. Copyright
copyright American Academy of Addiction Psychiatry.
ISSN 1055-0496
Publication Type Journal: Article
Journal Name American Journal on Addictions
Volume 16
Issue Part 3
Page 160-165
Year of Publication 2007
Date of Publication May 200COMORBIDITY
<103>
Database EMBASE
Accession Number 2007325465
Authors Sbrana A. Bizzarri J.V. Rucci P. Gonnelli C. Massei J.G. Ravani L. Endicott J. Maser J.D. Cassano G.B.
Institution
(Sbrana, Gonnelli, Massei, Ravani, Cassano) Dipartimento di Psichiatria, Neurobiologia, Farmacologia e
Biotecnologie, Universita' di Pisa, Pisa, Italy.
(Bizzarri) Servizio Per Le Dipendenze, Azienda Sanitaria di Bolzano, Bolzano, Italy.
(Rucci) Western Psychiatric Institute and Clinic, University of Pittsburgh, Pittsburgh, PA, United States.
(Endicott) Department of Psychiatry, Columbia University, New York, NY, United States.
(Maser) Department of Psychiatry, University of California, San Diego, CA, United States.
(Maser) Veterans Affairs San Diego Healthcare System, San Diego, CA, United States.
(Sbrana) Department of Psychiatry, Neurobiology, Pharmacology and Biotechnologies, University of Pisa, Via
Roma 67, 56127 Pisa, Italy.
Country of Publication
United Kingdom
Title
Family history of psychiatric disorders and alcohol and substance misuse in patients
with bipolar I disorder, substance use disorder, or both.
Source
American Journal on Addictions. 16(3)(pp 227-231), 2007. Date of Publication: May 2007.
Abstract
Family history data were collected on first-degree relatives of 78 patients with bipolar I
disorder (BD) and substance use disorder (SUD), 47 with BD only, and 35 with SUD only. The
prevalence of psychiatric disorders was significantly higher in first-degree relatives of patients
with BD + SUD (64%) and BD (61%) compared with first-degree relatives of SUD patients
(20%). The prevalence of alcohol misuse was significantly higher in first-degree relatives of
patients with BD + SUD (23.1%) and SUD alone (28.6%) compared to first-degree relatives of
patients with BD (4.3%). Our findings suggest that BD and SUD do not share familial risk
factors. Copyright copyright American Academy of Addiction Psychiatry.
ISSN 1055-0496
Publication Type Journal: Article
Journal Name American Journal on Addictions
Volume 16
Issue Part 3
Page 227-231
Year of Publication 2007
Date of Publication May 2007
COMORBIDITY <111>
Database EMBASE
Accession Number 2007312821
Authors Degenhardt L. Tennant C. Gilmour S. Schofield D. Nash L. Hall W. McKay D.
Institution
(Degenhardt, Gilmour) National Drug and Alcohol Research Centre, University of New South Wales, Sydney, NSW
2052, Australia.
(Tennant, Schofield, Nash) University of Sydney, Psychological Medicine, Royal North Shore Hospital, St Leonards,
NSW, Australia.
(Hall) School of Population Health, University of Queensland, St Lucia, QLD, Australia.
Country of Publication
United Kingdom
Title
The temporal dynamics of relationships between cannabis, psychosis and depression
among young adults with psychotic disorders: Findings from a 10-month prospective
study.
Source
Psychological Medicine. 37(7)(pp 927-934), 2007. Date of Publication: Jul 2007.
Abstract
Background. The aim was to examine the temporal relationships over 10 months between
cannabis use and symptoms of psychosis and depression in people with schizophrenia and
related disorders. The design was a prospective study of 101 patients with schizophrenia and
related disorders who were assessed monthly over 10 months on medication compliance,
cannabis and other drug use, symptoms of depression and symptoms of psychosis. Method.
Linear regression methods to assess relationships between cannabis use and symptoms of
psychosis and depression while adjusting for serial dependence, medication compliance and
other demographic and clinical variables. Results. Cannabis use predicted a small but
statistically significant increase in symptoms of psychosis, but not depression, after controlling
for other differences between cannabis users and non-users. Symptoms of depression and
psychosis did not predict cannabis use. Conclusion. Continued cannabis use by persons with
schizophrenia predicts a small increase in psychotic symptom severity but not vice versa.
copyright 2007 Cambridge University Press.
ISSN 0033-2917
Publication Type Journal: Article
Journal Name Psychological Medicine
Volume 37
Issue Part 7
Page 927-934
Year of Publication 2007
Date of Publication Jul 2007
COMORBIDITY <112>
Database EMBASE
Accession Number 2007312819
Authors Macleod J.
Institution
(Macleod) Department of Primary Care and General Practice, Primary Care Clinical Sciences and Learning Centre
Building, University of Birmingham, Birmingham B15 2TT, United Kingdom.
Country of Publication
United Kingdom
Title
Cannabis use and symptom experience amongst people with mental illness: A
commentary on Degenhardt et al.
Source
Psychological Medicine. 37(7)(pp 913-916), 2007. Date of Publication: Jul 2007.
Abstract
A high proportion of people who have a serious mental illness also use non-prescribed
psychoactive drugs. This association is perhaps most apparent, and possibly also has the
greatest implications for health, in relation to tobacco use. In fact recognition of the special
relationship between mental illness and smoking was recently reflected in exemption of
psychiatric units from legislation to ban smoking in enclosed public spaces in the UK (UK
Smoking Law Resource Centre, 2007). The prevalence of tobacco use has generally
decreased in most European, North American and Australasian countries, however, use of
other psychoactive drugs, has not followed this pattern (Advisory Council on the Misuse of
Drugs, 2006). Cannabis use in particular is widespread, both in the general population but
especially so amongst people with serious and enduring mental illness, particularly psychotic
illness. Recognition of the particular coincidence of cannabis use with psychotic illness
amongst psychiatric patients was one of the observations that precipitated current debate
around the possible aetiological role of cannabis use in relation to incidence of schizophrenia
(Thornicroft, 1990; Hall, 2006; Macleod et a. 2006). copyright 2007 Cambridge University
Press.
ISSN 0033-2917
Publication Type Journal: Note
Journal Name Psychological Medicine
Volume 37
Issue Part 7
Page 913-916
Year of Publication 2007
Date of Publication Jul 2007
COMORBIDITY <113>
Database EMBASE
Accession Number 2007312818
Authors Morgan C.
Institution
(Morgan) Institute of Psychiatry, London, United Kingdom.
Country of Publication
United Kingdom
Title
In this issue.
Source
Psychological Medicine. 37(7)(pp 911-912), 2007. Date of Publication: Jul 2007.
Abstract
This issue contains a commentary on the paper by Degenhardt et al. and one review on
participant distress in psychiatric research. Other sets of papers examine various aspects of
cannabis and other substance use disorders, borderline and other personality disorders, and
six individual papers examine a variety of topics. copyright 2007 Cambridge University Press.
ISSN 0033-2917
Publication Type Journal: Editorial
Journal Name Psychological Medicine
Volume 37
Issue Part 7
Page 911-912
Year of Publication 2007
Date of Publication Jul 2007